The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: A randomized clinical trial - 24/04/13
, Matthias Augustin, MD b, James Signorovitch, PhD c, Andrew P. Yu, PhD c, Eric Q. Wu, PhD c, Shiraz R. Gupta, PharmD d, Yanjun Bao, PhD d, Parvez Mulani, PhD d
Reprint requests: Alan Menter, MD, Baylor University Medical Center, Texas Dermatology Associates, 3900 Junius St, Suite 145, Dallas, TX 75246.Abstract |
Background |
Psoriasis is associated with health-related quality-of-life impairment and depression.
Objective |
We sought to determine the effect of adalimumab on depression symptoms in patients with psoriasis.
Methods |
Patients with moderate to severe psoriasis in a randomized, placebo-controlled, double-blind clinical trial were assessed for depression symptoms at baseline and week 12 or early termination (ET) using the Zung Self-rating Depression Scale (ZDS). The effects of adalimumab (40 mg every other week) versus placebo on ZDS score at week 12/ET were assessed using analysis of covariance. Relationships between ZDS and the Psoriasis Area and Severity Index (PASI), the Dermatology Life Quality Index, and the Short Form 36 Health Survey were assessed using Pearson correlations. Changes in ZDS score were compared for patients with and without a 75% or greater reduction in baseline PASI score.
Results |
Compared with the placebo group (n = 52), the adalimumab group (n = 44) experienced an additional 6-point reduction in ZDS score (95% confidence interval: 2.5-9.5; P < .001) by week 12/ET. Depression improvement was correlated with improvement in PASI (r = 0.5; P < .0001) and Dermatology Life Quality Index (r = 0.5; P < .0001). Greater ZDS score improvement was observed at week 12/ET in responders with a 75% or greater reduction in baseline PASI score than in nonresponders (10.6 [SD = 9.4] vs 1.4 [SD = 9.6]; P < .001).
Limitations |
This analysis cannot distinguish whether adalimumab has a direct or indirect effect on depression.
Conclusions |
Adalimumab treatment reduced psoriasis symptoms, reduced depression symptoms, and improved health-related quality of life in patients with moderate to severe psoriasis.
Le texte complet de cet article est disponible en PDF.Key words : adalimumab, depression, psoriasis, tumor necrosis factor
Abbreviations used : DLQI, ET, HRQOL, MCS, PASI, PASI 75, PCS, TNF, ZDS
Plan
| Supported by Abbott Laboratories. |
|
| Disclosure: Dr Menter is on advisory boards for, has received consulting fees from, and is on speakers bureaus for Abbott, Amgen, Centocor, Genentech, and Wyeth; and is an investigator for Abbott, Amgen, Centocor, and Genentech. Dr Augustin is on advisory boards for Abbott, Centocor, Janssen-Cilag, Schering-Plough, and Wyeth; is an investigator for Abbott, Biogen, Centocor, Janssen-Cilag, Schering-Plough, and Wyeth; and is on speakers bureaus for Abbott, Biogen, Janssen-Cilag, Schering-Plough, and Wyeth. Drs Signorovitch and Yu are employees of Analysis Group Inc. Dr Wu is an employee of Analysis Group Inc and a consultant for Abbott. Drs Gupta, Bao, and Mulani are employees of Abbott. |
Vol 62 - N° 5
P. 812-818 - mai 2010 Retour au numéro
Article précédent
- Characterization of Staphylococcus aureus cutaneous infections in a pediatric dermatology tertiary health care outpatient facility
- Alex G. Ortega-Loayza, Stephanie A. Diamantis, Peter Gilligan, Dean S. Morrell
- Four novel ATP2A2 mutations in Slovenian patients with Darier disease
- Aleksandar Godic, Branka Korošec, Jovan Miljković, Aleksej Kansky, Damjan Glavač
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?